THE PROSTATE CANCER FOUNDATION ANNOUNCES 2022 CHALLENGE AWARDS TOTALING MORE THAN $12 MILLION FOR PROSTATE CANCER RESEARCH

LOS ANGELES, Jan. 31, 2023 /PRNewswire/ — The Prostate Most cancers Basis (PCF) at present introduced the 2022 Class of PCF Workforce Problem Award recipients and a complete of greater than $12 million in funding for revolutionary prostate most cancers analysis.

Visit pcf.org.

Go to pcf.org.

PCF Problem Awards fund worldwide, multi-institutional, cross-disciplinary groups of investigators conducting extremely revolutionary analysis with the best potential for accelerating new and improved therapies for superior prostate most cancers. Following a rigorous peer assessment course of that assessed every undertaking’s scientific benefit and potential affected person affect, 15 extremely coveted PCF Problem Awards totaling greater than $12 million had been granted to groups at among the world’s main most cancers analysis establishments.

For full undertaking descriptions go to https://www.pcf.org/c/challenge-awards-class-of-2022/

2022 Movember-PCF Problem Award 
Undertaking Title: The Fee Parts Skewing Outcomes Linked to Veteran Fairness in PCa (RESOLVE PCa) Consortium: Multilevel Modeling to Predict Prostate Most cancers Incidence and Aggressiveness 
(Using scientific, demographic, and genetic knowledge from over 500,000 Veterans, to determine social and environmental vs. genomic/genetic elements that contribute to prostate most cancers racial disparities and develop improved affected person screening and administration methods.) 
Workforce Leaders: Isla Garraway, MD, PhD (College of California, Los Angeles; Larger Los Angeles VA Healthcare System); Kara Maxwell, MD, PhD (College of Pennsylvania; Corporal Michael J. Crescenz VA Medical Middle); Kosj Yamoah, MD, PhD (Moffit Most cancers Middle); Timothy Rebbeck, PhD (Dana-Farber Most cancers Institute; Harvard TH Chan College of Public Well being); Brent Rose, MD (College of California, San Diego)

2022 Movember-Distinguished Gentleman’s Journey-PCF Problem Award 
Undertaking Title: IRONMAN: Enhancing Survivorship in Sufferers with Superior Prostate Most cancers 
(Utilizing scientific and patient-reported knowledge from the worldwide IRONMAN registry to determine methods to scale back disparites and enhance high quality of life and outcomes in sufferers with superior prostate most cancers.)  
Workforce Leaders: Lorelei Mucci, ScD, MPH (Harvard T.H. Chan College of Public Well being); Daniel George, MD (Duke College)

2022 Michael & Lori Milken Household Basis-PCF Problem Award 
Undertaking Title: Mechanisms of Response and Resistance to DLL3-Focused T Cell Engager Remedy 
(Investigating a brand new DLL3-targeted immunotherapy for neuroendocrine prostate most cancers and figuring out methods to enhance affected person choice and remedy efficacy.)  
Workforce Chief: Himisha Beltran, MD (Dana-Farber Most cancers Institute)

2022 Stewart Rahr Basis-PCF Problem Award 
Undertaking Title:  Hormonal Shock Remedy for Metastatic Castrate Resistant Prostate Most cancers 
(Learning the mechanisms and efficacy of a brand new remedy strategy that mixes bipolar androgen remedy (BAT) with a remedy that targets the polyamine pathway in sufferers with metastatic castration resistant prostate most cancers.) 
Workforce Leaders: Samuel Denmeade, MD (Johns Hopkins College); Robert Casero, PhD (Johns Hopkins College); Erika Pearce, PhD (Johns Hopkins College)

2022 John Black Charitable Basis-PCF Problem Award 
Undertaking Title: First-In-Man PARP1-Selective Inhibitor in Deadly Prostate Most cancers: Mechanisms of Motion and Biomarkers of Therapeutic Response 
(Elucidating the biology of a mix PARP-inhibitor with anti-androgen remedy and creating a blood take a look at to pick which sufferers are almost certainly to profit from this remedy.)  
Workforce Leaders: Harveer Dev, MD, PhD (College of Cambridge); Simon Pacey, MD, PhD (College of Cambridge); Charlie Massie, PhD (College of Cambridge)

2022 Stupski Basis-PCF Problem Award 
Undertaking Title: Debunking the Frailty-SarcopenIa-ADT Axis in MEtastatic Prostate CanceR with MultiCompenent Exercise: The FIERCE Trial 
(Testing the affect of a multicomponent train intervention on frailty and sarcopenia in males present process remedy with androgen deprivation remedy and figuring out biomarkers of response and mechanisms by which train improves these capabilities.)  
Workforce Chief: Christina Dieli-Conwright, PhD, MPH (Dana-Farber Most cancers Institute)

2022 Patrice & Treasured Motsepe-PCF Problem Award 
Undertaking Title: Growing and Translating Progressive Methods to Therapeutically Goal Prostate Most cancers Lineage Plasticity 
(Testing the flexibility of a number of therapeutic approaches to forestall lineage plasticity and the event of castration resistant prostate most cancers.)  
Workforce Leaders: David Goodrich, PhD (Roswell Park Complete Most cancers Middle); Gurkamal Chatta, MD (Roswell Park Complete Most cancers Middle); Dean Tang, PhD (Roswell Park Complete Most cancers Middle); Dominic Smiraglia, PhD (Roswell Park Complete Most cancers Middle)

2022 PCF Problem Award 
Undertaking Title: Focusing on Lipid Metabolism and Eating regimen in Sufferers with Regionally Superior Prostate Most cancers 
(Testing the consequences of mixing a remedy focusing on the enzyme FASN with a weight loss plan that modulates the degrees of dietary lipids utilized in metabolic pathways that gasoline prostate most cancers.)   
Workforce Chief: Massimo Loda, MD (Weill Cornell Medication)

2022 John Black Charitable Basis-PCF Problem Award 
Undertaking Title: Epitranscriptomic Determinants of Therapy Resistance in Prostate Most cancers 
(Figuring out whether or not aberrant regulation of RNA methylation is a driver of enzalutamide resistance, and whether or not therapies focusing on methylation might overcome it.)  
Workforce Chief: Nigel Mongan, PhD (College of Nottingham)

2022 Michael & Lori Milken Household Basis-PCF Problem Award 
Undertaking Title:  Activating the NLRP3 Inflammasome to Deal with Superior Prostate Most cancers  
(Demonstrating the mechanisms and potential for NLRP3-activation as a brand new immunotherapeutic technique, alone or together with androgen deprivation remedy and/or checkpoint immunotherapy.)  
Workforce Leaders: Akash Patnaik, MD, PhD (College of Chicago); Amy Moran, PhD (Oregon Well being & Science College); David Sykes, MD, PhD (Massachusetts Normal Hospital)

2022 Igor Tulchinksy-Leerom Segal-PCF Problem Award 
Undertaking Title: Leveraging Poison Introns for Therapeutics and Diagnostics of Deadly Prostate Most cancers 
(Understanding the affect of minor intron splicing on prostate most cancers biology and remedy resistance and its potential as a threat evaluation biomarker.) 
Workforce Leaders: Mark Rubin, MD (College of Bern); Gunnar Rätsch, PhD (ETH Zurich); Rahul Kanadia, PhD (College of Connecticut)

2022 PCF Problem Award 
Undertaking Title:  Enhancing Antigen Presentation and Anti-Tumor Immunity for Prostate Cancers by means of an Intratumorally Delivered, Fc-Enhanced Anti-CD40 Antibody Remedy 
(Learning the efficacy and mechanisms of motion of a novel immunotherapy that targets the important thing immune activation pathway CD40 in sufferers with prostate most cancers.)  
Workforce Leaders: Howard Scher, MD (Memorial Sloan Kettering Most cancers Middle); Behfar Ehdaie, MD, MPH (Memorial Sloan Kettering Most cancers Middle); David Knorr, MD, PhD (Memorial Sloan Kettering Most cancers Middle); Matthew Dallos, MD (Memorial Sloan Kettering Most cancers Middle)

2022 PCF Problem Award 
Undertaking Title:  Focusing on B7-H3 in Aggressive Variant Prostate Most cancers 
(Figuring out the function of B7-H3 in aggressive types of metastatic castration resistant prostate most cancers and its potential as a therapeutic goal.)  
Workforce Leaders: Di Zhao, PhD (The College of Texas MD Anderson Most cancers Middle); Ana Aparicio, MD (The College of Texas MD Anderson Most cancers Middle); Sangeeta Goswami, MD, PhD (The College of Texas MD Anderson Most cancers Middle)

2022 Janssen – PCF Particular Problem Award 
Undertaking Title: Advancing the Drug Growth Course of in Metastatic Prostate Most cancers by means of Machine Studying 
(Utilizing a machine studying strategy to determine novel kinetic, multi-dimensional biomarkers that may precisely predict general survival and might function intermediate scientific endpoints to hurry scientific trials in metastatic prostate most cancers.)  
Workforce Leaders: Eric Small, MD (College of California, San Francisco); Rahul Aggarwal, MD (College of California, San Francisco); Julian Hong, MD, MS (College of California, San Francisco); David Quigley, PhD (College of California, San Francisco)

2022 Rely Me In – PCF Particular Problem Award for Metastatic Prostate Most cancers 
Undertaking Title: Metastatic Prostate Most cancers (MPC) Undertaking 
(Utilizing knowledge from over 1,000 sufferers to comprehensively profile the genomic panorama of metastatic prostate most cancers to find new biology and inform remedy methods.) 
Workforce Chief: Eliezer Van Allen, MD (Harvard: Broad Institute of MIT & Harvard)

In regards to the Prostate Most cancers Basis
The Prostate Most cancers Basis (PCF) is the world’s main philanthropic group devoted to funding life-saving prostate most cancers analysis. Based in 1993 by Mike Milken, PCF has been chargeable for elevating near $1 billion in assist of cutting-edge analysis by greater than 2,200 analysis tasks at 245 main most cancers facilities in 28 nations around the globe. Since PCF’s inception, and thru its efforts, sufferers around the globe live longer, struggling fewer problems, and having fun with higher high quality of life. PCF is dedicated to creating a worldwide public sq. for prostate most cancers, in service to our mission of ending demise and affected by the illness. Be taught extra at pcf.org.

MEDIA CONTACT:
Staci L. Vernick 
Prostate Most cancers Basis 
[email protected] 
[email protected] 
610-812-6092

Cision

Cision

View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/the-prostate-cancer-foundation-announces-2022-challenge-awards-totaling-more-than-12-million-for-prostate-cancer-research-301734422.html

SOURCE Prostate Most cancers Basis

Previous post Washington Huskies OC Ryan Grubb is not going to be a part of Alabama workers after assembly with Nick Saban
Next post Viji Krishna